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YKL-40 is a secreted protein that is highly up-regulated in malignant glioblastoma 
(GBM). Its expression is correlated with the invasive nature of GBMs and poor diagnosis 
of patients (Nigro et al., 2005).  Previous research has shown that in astrocytes and GBM 
cells, YKL-40 expression is regulated by two transcription factors, NFI-X3 and STAT3, 
which form a complex with each other (Singh et al., 2011).  Here, we show that the N-
terminal domain of NFI-X3 is sufficient and required for its interaction with STAT3.  We 
also show that the DNA-binding domain of NFI-X3 is required to induce YKL-40 
expression. Thus, the interaction of NFI-X3 with STAT3 may play a role in stabilizing the 
xi 
 
otherwise weak binding of NFI-X3 to the YKL-40 promoter.  Collectively, the 
observations made in this study shed light on the mechanisms by which NFI-X3, in concert 
with STAT3 regulate YKL-40 expression.       
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CHAPTER 1:  Analysis of NFI-X3 
and STAT3 interaction and its 
function  
 
 Introduction 
Glioblastoma:  
 Glioblastoma multiforme (GBM), also known as grade IV malignant glioma, is the 
most common primary brain tumor. In the United States, GBM affects 13,000 people each 
year (Ohgaki et al., 2005).  These tumors are highly aggressive, infiltrative, and 
destructive, making current treatments, such as surgical resection, radiation and 
chemotherapy ineffective (Schwartzbaum et al., 2006).  The average time of survival after 
diagnosis is 14 months (Stupp et al., 2005).  Although the molecular signaling pathways 
implicated in this disease are not well understood, recent research has shown that several 
signaling pathways may be involved.  These pathways include phosphoinositide-3 kinase, 
AKT, Ras, and mitogen-activated protein kinase (MAPK), and receptor tyrosine kinases, 
including epidermal growth factor receptor (EGFR) and the vascular endothelial growth 
factor receptor (VEGFR). All of these pathways contribute to the growth and promotion of 
glioblastoma (Rao et al., 2004 and Guha et al., 2004). Recently, genes that are 
glioblastoma targeted have been elucidated and include, Tp53 (gene encoding p53), Rb, 
and PTEN.  Moreover, a secreted glycoprotein, YKL-40 is overexpressed in patients with 
GBM and is associated with the strong vascularized phenotype of GBM.    
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YKL-40: 
YKL-40, a member of the mammalian chitinase-like proteins is highly expressed in 
many types of cancers, including glioblastoma.  The YKL-40 gene located on chromosome 
1q31-q32 is 8 kb long and consists of 10 exons (Rehli et al., 2003).  It contains a single 
polypeptide chain of 383 amino acids (Hakala et al., 1993). YKL-40 is named for its three 
NH2-terminal amino acids Tyrosine (Y), Lysine (K) and Leucine (L) and its molecular 
weight of 40 kDa.   As a member of the glysosyl chitinase family 18, YKL-40 can bind to 
chitin of different lengths (Aronson et al., 1997).   Chitinases contain three amino acids 
that are essential for their glycolytic activity: Asp, Glu and Asp.  In YKL-40, the Glu 
residue is replaced by Leu and as a result, YKL-40 does not have chitinase activity 
(Renkema et al., 1998). YKL-40 contains two possible sites of glycosylation, but only the 
NH2-terminal is glycosylated with two units of N-acetylglucosamine via β(1-4) linkage.  It 
contains a binding site for heparin and two binding sites for hyaluronan acid (Fusetti et al., 
2003).   
Many cells secrete YKL-40, including macrophages, chondrocytes and synovial 
cells (Krause et al., 1996, Hakala et al., 1993).  YKL-40 is a growth factor for fibroblasts, 
synovial cells and chondrocytes (De Ceuninck et al., 2001, Recklies et al., 2002, Ling et 
al., 2004).  In fibroblasts, YKL-40 initiates mitogen-activated protein kinase and PI-3-
kinase signaling cascades leading to the phosphorylation of both ERK 1/2 and protein 
kinase B (AKT) (Recklies et al., 2002 and Ling et al., 2004).  As this signaling cascade is 
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associated with the control of mitogenesis, it is indicative of a role of YKL-40 as an anti-
apoptotic protein.   
YKL-40 is one of the most highly expressed genes in GBM and is secreted in vitro 
by human glioma cell lines (Nigro et al., 2005).   Even though its role in cancer is not yet 
fully understood, it is believed that YKL-40 may play a role in the proliferation and 
differentiation of malignant cells, protection of cancer cells from undergoing apoptosis, 
stimulating angiogenesis and tissue remodeling.  In immortalized astrocytes, YKL-40 
increases resistance to radiation and increased invasion in vitro (Nigro et al., 2005).  YKL-
40 also plays a role in angiogenesis by stimulating the migration and re-organization of 
vascular endothelial cells (Malinda et al., 1999).  Recently, it was shown that YKL-40 can 
act as an independent angiogenic factor and can also up-regulate VEGF, resulting in a 
synergistic effect on angiogenesis.    In addition, YKL-40- induced angiogenesis is 
dependent on the interaction between membrane receptors syndecan-1 (Syn-1) and integrin 
αvβ3 (Francescone et al., 2011).     
Moreover, mice lacking YKL-40 gene have impaired antigen induced Th2 
responses with YKL-40 acting as a potent inhibitor of death-receptor induced 
inflammatory cell apoptosis. The expression of IL-4 and IL-13 was decreased in YKL-40 
null animals challenged with antigen compared to sham treated animals (Lee et al., 2009).   
Even though YKL-40 has recently received much attention as a diagnostic marker 
for many diseases, little is known about its regulation.  The YKL-40 promoter contains 
binding sites for many transcription factors, including: PU.1, Sp1, Sp3, USF, AML-1 and 
4 
 
C/EBP (Rehli et al., 2003).  Also, NF-κB, specifically its p65 and p50 subunits, negatively 
regulates YKL-40 in glioma cells (Bhat et al., 2008).  Furthermore, YKL-40 expression in 
the brain is regulated by Nuclear Factor I-X (NFI-X) and Signal Transducers and 
Activators of Transcription 3 (STAT3) (Singh et al., 2011).  
     
Signal Transducers and Activators of Transcription (STAT): 
Signal Transducers and Activators of Transcription proteins regulate many aspects 
of growth, survival and differentiation in cells.  In the human genome, STATs are clustered 
on three chromosomes and consist of seven mammalian members (STAT1, 2, 3, 4, 5a, 5b 
and 6).  STAT proteins are between 700-850 amino acids long and contain many 
functional domains.  They consist of an N-terminal protein interaction domain, coiled-coil 
domain, DNA binding domain, linker domain, SH2 domain and transactivation domain.  
At the C-terminus, all STATs contain a conserved Tyr residue that upon phosphorylation, 
interacts with the SH2 domain and allows their dimerization.  Most STATs, excluding 
STAT2 and STAT6, contain a second conserved Ser residue at the transactivation domain 
that can be phosphorylated.  The N-terminus of STATs is involved in dimerization, 
tetramerization and protein-protein interactions (Vinkemier et al., 1998). The coiled-coil 
domain is involved in the interaction with other proteins and may play a role in receptor 
binding (Zhang et al., 2000).  The DNA binding domain assumes an immunoglobulin-fold 
structure and is involved in nuclear translocation by maintaining proper conformation for 
importin binding (Ma et al., 2006).  The linker domain is involved in transcriptional 
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activation (Yang et al., 1999) and protein-protein interaction (Lufei et al., 2003).  The SH2 
domain, the most conserved domain, is critical for receptor association and phospho-dimer 
formation.  The least conserved transactivation domain is involved in protein-protein 
interaction with CBP (p300)-binding protein and many other proteins, which leads to the 
specific activation of transcription (Zhang et al., 1996).  STAT1 and STAT2 dimerize and 
can form a complex with IRF9 to bind the Interferon Sensitive Response Element (ISRE), 
while all other STATs bind to the Gamma interferon Activation Site (GAS) element.   
STATs are activated by many cytokines, growth factors and hormones. STAT1 
activation is induced by IFN-α/β/γ.  STAT1 is involved in anti-viral and anti-bacterial 
response, growth inhibition, apoptosis and tumor suppression. STAT2 is involved in IFN 
response.  STAT3 is activated by cytokines and growth factors, such as IL-6 family 
members and EGF.  STAT3 functions in wound-healing, regeneration of liver, mammary 
involution and survival of many cell types and is the only STAT that is required for early 
development (Takeda et al., 1997, Akira, 2000 and Poli et al., 2003).  It is involved in 
survival, anti-apoptosis, mitogenesis and oncogenesis (Bromberg, 2001).  STAT4 is 
induced by IL-12 and is involved in Th1 development, whereas STAT6 is involved in Th2 
development and is activated by IL-4.  STAT5a is involved in prolactin hormone signaling 
and STAT5b is involved in growth hormone signaling.  
 Upon activation, STATs are Tyrosine phosphorylated, which is important for their 
dimerization, nuclear import, DNA binding and transcriptional activation.  This activation 
can take place by many mechanisms. Binding of cytokines leads to dimerization of the 
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cytokine receptors, which then leads to activation of the receptor-associated tyrosine 
kinase, Janus Kinases (JAKs).  JAKs then trans-phosphorylate Tyr residues in the 
intracellular domain of the receptor.  The phosphorylated Tyrosines provide a binding 
scaffold for STATs, which are recruited to the receptor via their SH2 domains.  JAKs then 
phosphorylate STATs on a specific Tyr residue on the cytoplasmic tail, allowing them to 
form homo- or hetero- dimers by reciprocal binding of the phospho-Tyr to the SH2 domain 
of the partner.  Upon dimerization, STATs dissociate from the receptor, translocate to the 
nucleus by associating with importins, bind DNA and activate the transcription of 
cytokine-responsive genes.  Another mode of activation is with receptors that have 
intrinsic tyrosine kinase activities, which activate STATs directly. Yet another mechanism 
is via non-receptor tyrosine kinases, often used by viral oncoproteins that lead to 
constitutive activation of STATs.  
Inactivation of STATs is regulated by many mechanisms, including the cytokine-
inducible SH2-containing protein (CIS), suppressor of cytokine signaling (SOCS), STAT 
inhibitor (SSI), protein inhibitor of activated STAT (PIAS) and phosphatases as well as the 
ubiquitin-proteosome pathway (Kim, 1996).  The family of SOCS/CIS proteins suppresses 
cytokine signaling by several mechanisms including competition for phosphor-Tyr binding 
and promoting degradation of signaling molecules via ubiquitination (Starr et al., 2003), 
whereas the PIAS family interact directly with phosphorylated STATs in the nucleus and 
block their binding to DNA.  
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STATs play a central role in determining immune responses in cytokine-dependent 
inflammation and immunity.  These proteins may control whether immune responses in the 
tumor environment promote or inhibit cancer.  While STAT1, STAT5 and STAT6 are 
involved in inhibiting anti-tumor immunity, STAT3 regulates genes that are involved in 
tumor proliferation, survival, angiogenesis and invasion (Yu et al., 2007).  STAT3 
activation promotes tumor growth by antagonizing NF-κB and STAT1-mediated anti-
tumor response and mediating T regulatory cell expansion and TH17 development (Wang 
et al., 2009; Wu et al., 2009).  STAT3 induces the expression of cytokines and 
chemokines, such as COX2 and IL-6 that are associated with cancer-promoting 
inflammation.  Thus, STAT3 forms an autocrine and paracrine feed- forward loop that 
results in promotion of cancer.  Additionally, STAT3 is constitutively activated in almost 
all human glioblastoma multiforme tissue.  Furthermore, GBMs have higher expression 
levels of IL-6 and OSM, leading to constant activation of STAT3 signaling (Lim and Cao, 
2006).  
Nuclear Factor I (NFI): 
 The Nuclear Factor I family of transcription factors constitutes of four DNA-
binding proteins, NFI-A, NFI-B, NFI-C, and NFI-X, which regulate the transcription of 
many cellular and viral genes as well as viral DNA replication.  They are encoded by four 
highly conserved genes: Nfia, Nfib, Nfic, and Nfix.  NFI proteins form homo- and hetero- 
dimers to bind the consensus sequence TTGGC(N)5GCCAA on duplex DNA 
(Henninghausen et al., 1985, Leegwater et al., 1985, and Nowock et al., 1985).  
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In vertebrates, the four NFI genes are alternatively spliced yielding multiple mRNA 
and proteins from each gene. However, all isoforms of NFIs contain a conserved N-
terminal DNA-binding and dimerization domain. The DNA-binding and dimerization 
domain is 200 amino acids long and is highly conserved within the four genes.  This 
domain is enough for DNA-binding, dimerization and stimulation of adenoviral DNA 
replication (Mermod et al., 1989, Gounari et al., 1990) and is preceded by exons encoding 
8-47 amino acid domain of unknown function, but is strongly conserved between the four 
genes (Meisterernst et al., 1989).   Point mutations made in this region have shown that 
dimerization is needed for DNA-binding activity; however, DNA-binding ability can be 
eliminated independently of dimerization activity (Armentero et al., 1994).  The N-
terminal 1/3 of the DNA-binding and dimerization domain contains a highly basic alpha-
helix.  This helix consists of Lysine and arginine residues spaced at seven amino acid 
intervals (Meisterernst et al., 1989). The C-terminal 2/3 of the DNA-binding and 
dimerization domain contains four cysteine residues that are conserved between all NFI 
DNA-binding domains.  Three of these cysteines (Cys 104, 120, and 163 in human NFI-C) 
are required for DNA-binding (Novak et al., 1992).  The fourth cysteine (Cys 157) is 
important for protection to oxidative damage, but is not needed for DNA-binding activity 
(Bandyopadhyay et al., 1998).  
The N-terminal domain is responsible for the DNA-binding and replication 
activities of NFI proteins.  On the other hand, the C-terminal domain of NFI proteins 
regulates gene expression.  Alternative splicing generates many variants of the C-terminal 
domains; however, cloning and characterization of NFI-C transcripts show that residues 
9 
 
399-499 are required for maximal transcriptional activity.  This region is rich in proline 
residues and when linked to DNA-binding domains can induce a five-to-ten fold increase 
in transcription (Mermoid et al., 1989).  Apart from its transcriptional activation, the C-
terminal domain also includes a repression domain that inhibits transcription from many 
promoters, including GLUT4 genes (Adams, et al., 1995).  Although the exact mechanism 
of repression is not known, direct competition with transactivators for binding has been 
shown (Nehls et al., 1991, 1992).  
During embryogenesis of mammals, the NFI genes are expressed in overlapping 
patterns. NFI-A, -B and –X are highly expressed in the neocortex (Chaudhry et al., 1997).   
As a result, knockout of Nfia and Nfib genes in mice caused neuroanatomical defects, 
including a 5-10 fold decrease in the expression of astrocyte markers including Glial 
Fibrillary Acidic Protein (GFAP) (Shu et al., 2003, Steele-Perkins, 2005 and Neves, das L., 
1999). Additionally, Nfib deficient mice die due to defects in lung development along with 
abnormal hippocampus and pons formation (Steele-Perkins et al., 2005).  Nfic gene 
knockout causes early postnatal tooth formation defects (Steele-Perkins et al., 2003).  Nfix 
gene knockout causes hydrocephalus and agenesis of the corpus collosum and leads to 
postnatal lethality in most animals (Driller et al., 2007).  These knockout phenotypes of 
Nfia, Nfib, and Nfix indicate their roles in normal brain development.  NFI-C and –X 
regulate expression of astrocyte markers during differentiation of neural precursors in vitro 
(Wilczynska, 2009).  However, these transcription factors also play a role in abnormal 
brain physiology, such as gliogenesis (Deneen et al., 2006).  
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Recently, our lab has cloned and analyzed a novel splice variant of the nfix gene, 
NFI-X3.   This variant contains a unique transcriptional activation (TA) domain 
completely conserved in primates.  Compared to NFI-X1, the overexpression of NFI-X3 
more potently activates NFI reporters, including GFAP reporter, in astrocytes and glioma 
cells.  NFI-X3 expression is upregulated during the differentiation of neural progenitors to 
astrocytes and precedes the expression of astrocyte marker, GFAP and Secreted Protein 
Acidic Rich Cystein Like-1. The overexpression of NFI-X3 upregulates the expression of 
these marker genes in astrocytes and glioma cells. The TA domain of NFI-X3 activates 
GFAP expression by causing changes in the architecture of the +1 nucleosome that lead to 
the increased recruitment of RNA polymerase II (Singh et al., 2011).  Additionally, our lab 
identified YKL-40 as a target gene of NFI-X3 in astrocytes and glioma cells that controls 
their migration.  YKL-40 expression is activated during mouse brain development and also 
during the differentiation of neural progenitors into astrocytes in vitro. In primary 
astrocytes, YKL-40 expression is also controlled by STAT3. The knock-down of NFI-X 
and STAT3 significantly reduced YKL-40 expression in astrocytes, while overexpression 
of NFI-X3 induced YKL-40 expression in glioma cells. In addition, we have found that 
STAT3 and NFI-X3 activate YKL-40 expression via their binding site located in the YKL-
40 proximal promoter (Singh et al., 2011). Moreover, we have found that NFI-X and 
STAT3 physically interact and it is possible that this complex may regulate YKL-40 
expression.  
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Hypothesis 
STAT 3 and NFI-X3 control GFAP expression both in astrocytes and GBM cells.  
Both of these transcription factors bind to their corresponding regulatory elements on the 
enhancer region and cause the eviction of nucleosome of the GFAP promoter and induce 
its expression (Singh et al., 2011). However, how these transcription factors regulate YKL-
40 expression is not known.  Our lab showed that a YKL-40 reporter gene lacking four 
NFI elements is fully activated by Oncostatin M, whereas the deletion of the proximal 
STAT element (-78 to -69) significantly reduces reporter activity.  Furthermore, NFI-X3 
and STAT3 weakly bind to their juxtaposed elements in the YKL-40 promoter in vitro and 
STAT3 co-immunoprecipitates with NFI-X3 from U373 cells (Singh et al., 2011). Thus, 
we hypothesize that STAT3 may recruit NFI-X3 to the YKL-40 promoter.  In fact, we 
suspect that there is a direct interaction between STAT3 with NFI-X3 that is needed for the 
regulation of YKL-40 expression.  Therefore, we hypothesize that this complex regulates a 
subset of genes, as is true for the NF-κB/STAT3 complex (Yang J. et al., 2007 and Yu et 
al., 2002).   The aim of this thesis is to identify the specific regions in NFI-X3 that are 
required for its interaction with STAT3 and show that the NFI-X3/ STAT3 complex 
regulates a subset of genes, including YKL-40.   
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Materials and Methods 
Cell culture and reagents: Human glioblastoma U373-MG cells and human embryonic 
kidney HEK293 cells were provided by American Type Culture Collection (Rockville, 
MD).  These cells were cultured in Dulbecco’s modified Eagle’s medium supplemented 
with 10% fetal calf serum, antibiotics, and non-essential amino acids.   
Plasmids and site-directed mutagenesis: pSTAT3-V5 and vector expressing full-length 
NFI-X3FLAG was obtained from Singh et al., (2011).  The following deletions and point 
mutations of NFI-X3FLAG were made using QuikChange® II Site-Directed Mutagenesis 
Kit (Stratagene, Cedar Creek, TX) following their protocol.  The above vector was used as 
a template and primers were ordered from Eurofins MGE Operon, Huntsvillle, AL.  The 
forward 5’-CACCGGACAGAGGTCCGGAACCGATTACAAGGACGACG- 3’ and the 
reverse 5’-GGTTCCGGACCTCTGTCCGGTGGCCTGG-3’ primers were used to delete 
84 amino acids from the C-terminus of NFI-X3FLAG (NFI-X3FLAG-del 1).  Plasmid 
containing deletion was analyzed with AccIII.  The forward, 5’- TGTGGATGCAAGGTC 
CGGAACCGATTACAAGGACGACG-3’ and the reverse, 5’-GGTTCCGGACCTTGCA 
TCCACATCGTTGG-3’ primers were used to delete 184 amino acids from the C-terminus 
(NFI-X3FLAG-del 2).  Plasmid containing this deletion was analyzed with BstXI.  The 
forward, 5’- TTTTGTGACTAGGTCCGGAACCGATTACAAGGACGACG-3’ and the 
reverse, 5’- GGTTCCGGACCTAGTCACAAAACAGTCCTGG-3’ primers were used to 
delete 284 amino acids from the C-terminus (NFI-X3FLAG-del 3).  Plasmid containing 
this deletion was analyzed with AccIII.  The NFI-X3FLAG N-terminus α-helix deletion 
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(NFI-X3FLAG-NT del) was made using the forward, 5’-
TCGCCATGGATGAGTTCCGCGAGGACTTCG-3’ and the reverse, 5’-
TCGCGGAACTCATCCATGGCGAAGCTTGAATTC-3’ primers.  The plasmid 
containing this deletion was analyzed with Hind III.  The NFI- X3FLAG C148L, C154L 
(NFI-X3FLAG-C148L, C154L) point mutations were made by using the forward, 5’-
CTCAGCTGTCGAACCCCGGCCTGCTCGTCCAGCCACATCACATTG-3’ and the 
reverse, 5’-TGGACGAGCAGGCCGGGGTTCGACAGCTGAGGCGACTTGTAGAGC -
3’ primers.  The plasmid containing these point mutations was analyzed with PvuII.   
Transient Co-transfections: HEK293 cells were transiently transfected in 6 well clusters 
using Lipofectamine LTX and PLUS Reagent (Invitrogen, Carlsbad, CA) using the 
supplier’s protocol.  On day 1, cells were transfected with 1 µg of NFI-X3FL, NFI-X3FL- 
del 1, NFI-X3FL- del 2, NFI-X3FL- del 3, NFI-X3FL-NT del and NFI-X3FL- C148L, 
C154L mutation.  On day 2, cells were transfected with 1 µg of pSTAT3-V5.  Two days 
after the intial transfection, cells were harvested, protein extracts were prepared, and 
protein concentration was determined by the BCA method (Sigma Chemical Co., St. 
Louis, MO).   
Stabe Transfections: Stable clones were generated in U373 cells by using 4 µg of NFI-
X3FL- C148L, C154L plasmid and 0.2 µg of a second plasmid containing either zeocine or 
hygromycin resistance gene.  Cells were transfected in 10 cm dishes and clones were 
selected in DMEM containing 100 µg/ml hygromycin and 300 µg/ml zeocine.     
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Western blotting: Cells were lysed in 1 ml of IP buffer (10 mM Tris 7.4, 150 mM sodium 
chloride, 1 mM EDTA, 0.5% NP-40, 1% Triton X-100, 1 mM sodium orthovanadate, and 
protease inhibitor cocktail (Roche, Mannheim, Germany)).  Samples were resolved using 
SDS-PAGE and electroblotted onto nitrocellulose membrane (Schleicher & Schuell, 
Keene, NH).  The blots were incubated with an anti-FLAG antibody (0.3 µg/ml) or an anti-
V5 antibody (1.2 mg/ml) overnight at 4°C.  The blots were washed extensively with a 
solution containing 0.15M NaCl, 0.01M Tris pH 8.0, and 1% NP-40.  The anti-FLAG 
antibody was purchased from Sigma-Aldrich, St. Louis, MO.  The anti-V5 antibody was 
purchased from Invitrogen, Carlsbad, CA.  Anti-mouse secondary antibody was used in 
both cases and antigen-antibody complexes were visualized by enhanced 
chemiluminescence using Immobilon Western blotting kit (Millipore, Temecula, CA).   
Co-Immunoprecipitation: Protein lysates were prepared as described in western blotting 
section. 20 µg/ml of FLAG beads (Sigma –Aldrich, St. Louis, MO) was added to tubes 
containing 200-300 µg of protein lysates and 1 ml of IP buffer and incubated overnight at 
4°C with rocking.  Immunoprecipitates were washed three times with 1 ml of IP buffer and 
once with 900 µl of 1X TBS (50 mM Tris pH 7.4, 150 mM NaCl).  Complexes were eluted 
using 15 µg of FLAG peptide and analyzed by SDS/PAGE (10% gels) followed by 
western blot.   
RNA isolation and quantitative PCR: Total cellular RNA was prepared using Trizol 
(Invitrogen, Carlsbad, CA), following the manufacturer’s protocol.  Subsequently, 1 µg of 
total RNA was reverse-transcribed using the High Capacity cDNA Archive kit (Applied 
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Biosystems, Foster City, CA).  YKL-40, GFAP, and GAPDH mRNA levels were 
measured using pre-mixed primer-probe sets, and TaqMan Universal PCR Master Mix 
(Applied Biosystems, Foster City, CA).  The cDNAs were diluted 10-fold for the GFAP 
and YKL-40 genes and 100-fold for GAPDH and amplified using the ABI 7900HT cycler.  
Gene expression levels were normalized to GAPDH mRNA levels, and presented as a fold 
induction with mean +/- standard deviation.   
Nuclear Localization: HEK293 cells were transfected with 1 µg of NFI-X3FL, NFI-
X3FL- del 1, NFI-X3FL- del 2, NFI-X3FL- del 3, NFI-X3FL-NT del and NFI-X3FL-
C148L, C154L mutations using Lipofectamine LTX and PLUS Reagent (Invitrogen, 
Carlsbad, CA) using the supplier’s protocol.  Twenty-four hours after transfection, cells 
were washed with non-sterile PBS three times, and fixed with 3% paraformaldehyde in 
1ml for 30 minutes at room temperature. After PBS washing twice, cells were 
permeabilized with 0.1% Triton-X for 20 minutes at room temperature.  After PBS 
washing twice, anti-FLAG (M2) (Sigma-Aldrich, Saint Louis, MO) antibody was prepared 
in 5% ELISA grade BSA (1:100 dilution)  and added to cells, which were then incubated at 
4°C overnight under moist conditions. Next day, cells were washed with PBS twice and 
Alexa Fluor® 488 anti-mouse IgG (Invitrogen, Carlsbad, CA)  was used as a secondary 
antibody (1:400 dilution), and cells incubated for thirty minutes in the dark.  After washing 
with PBS twice, Hoescht (50ng/ml) was added to the cells and incubated at room 
temperature for 3 minutes.  Cells were then washed with PBS twice.  After cells were 
mounted, they were visualized with Fluorescence microscopy and photographs were taken 
using Nikon Eclipse E1000 camera.  
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Results 
Mutations of NFI-X3 domains.   
In order to understand which domain of NFI-X3 is important for its interaction with 
STAT3, deletion mutants were constructed using synthetic oligonucleotides (Figure 1 and 
6).  Three constructs were generated in which amino acids were deleted from the C-
terminus: NFI-X3FL-del 1 lacked 84 amino acids (411-495), NFI-X3FL-del 2 lacked 184 
amino acids (311-495) and NFI-X3FL-del 3 lacked 284 amino acids (211-495).  To assess 
the proper generation of these deletion mutants, digestions with restriction enzymes were 
carried out and fragments visualized on 2% agarose gel with EtBr. In some cases, full- 
length NFI-X3FL was digested as a control. The sizes of the fragments were predicted by 
maps created using the ApE program.  NFI-X3FL-del 1 was digested with AccIII.  The 
full- length plasmid showed a fragment of 6108 bases, whereas del 1 showed two 
fragments, 696 and 5160 bases (Figure 2).  NFI-X3FL-del 2 plasmid was digested with 
BstXI.  The full length plasmid showed two fragments, 5072 and 1040 bases, whereas del 
2 showed fragments of 5074 and 489 bases (Figure 3).  NFI-X3FL-del 3 was digested with 
AccIII and showed two fragments of 5160 and 96 bases (Figure 4).   
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Figure 1: C-terminus deletions of NFI-X3FL. Synthetic oligonucleotides were used to 
create three deletion mutants of NFI-X3FL. These mutants were created using the NFI-
X3FL as a template and using the QuikChange® Site-Directed Mutagenesis kit and 
protocol. These mutants lack 84 amino acids (NFI-X3FL-del 1), 184 amino acids (NFI-
X3FL-del 2) and 284 amino acids (NFI-X3FL-del 3) from the C-terminus, as depicted 
below. NFI-X3 consists of N-terminal α-helix, DNA-binding domain as well as four 
conserved Cysteines within DNA-binding domain. On the C-terminus, NFI-X3 contains a 
transcriptional activation (TA) domain.   
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Figure 2: NFI-X3FL-del 1 plasmid digestion with AccIII. Synthetic oligonucleotides 
were used to delete 84 amino acids from the C-terminus of NFI-X3FL using the full-length 
NFI-X3FL as a template and following QuikChange® II Site-Directed Mutagensis Kit 
protocol. Plasmid containing this deletion was purified and digested with AccII. Digestion 
map showing the sizes of the predicted fragments of full-length and NFI-X3FL-del 1 were 
created using the ApE program.  
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Figure 3: NFI-X3FL-del 2 plasmid digestion with BstXI. Synthetic oligonucleotides 
were used to delete 184 amino acids from the C-terminus of NFI-X3FL using the full-
length NFI-X3FL as a template and following QuikChange® II Site-Directed Mutagensis 
Kit protocol. Plasmid containing this deletion was purified and digested with BstXI. 
Digestion map showing the sizes of the predicted fragments of full-length and NFI-X3FL-
del 2 were created using the ApE program.  
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Figure 4: NFI-X3FL-del 3 plasmid digestion with AccIII. Synthetic oligonucleotides 
were used to remove 284 amino acids from the C-terminus of NFI-X3FL using the full- 
length NFI-X3FL as a template and following QuikChange® II Site-Directed Mutagensis 
Kit protocol. Plasmid containing this deletion was purified and digested with AccIII. 
Digestion map showing the sizes of the predicted fragments of NFI-X3FL-del 3 was 
created using the ApE program. 
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The N-terminus of NFI-X3 is sufficient for its interaction with STAT3. 
 In order to investigate if the C-terminus of NFI-X3 was needed for its interaction 
with STAT3, an empty vector, full-length NFI-X3FL, NFI-X3FL-del1, NFI-X3FL-del 2, 
and NFI-X3FL-del 3 were transiently transfected in HEK cells along with STAT3-V5.  
Cells were lysed and ran on SDS-PAGE and expression of both STAT-V5 (92 kDa) 
(Figure 5C) and NFI-X3FLAG (Figure 5B) was analyzed by Western Blot.  Figure 5B 
shows the expression of the NFI-X3FL constructs: full length NFI-X3FL (56 kDa), del 1 
(45 kDa) , del 2 (36 kDa) and del 3 (26 kDa).   The same lysates were used to perform Co-
Immunoprecipitation.   Samples were then run on SDS-PAGE and result analyzed by 
Western Blot (Figure 5A). Results show that with similar expression of both STAT3-V5 
and NFI-X3FL, all three deletions are still able to interact with STAT3.  However, the 
interaction is weaker in cells containing the deletion mutants when compared to those 
transfected with full- length NFI-X3.         
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Figure 5: The N-terminus of NFI-X3 is sufficient for its interaction with STAT3.  
HEK293 cells were co-transfected with 1µg of STAT3-V5 and  1 µg of empty vector, full-
length NFI-X3 or NFI-X3 containing either del 1, del 2 or del 3. 20 µg of proteins from 
SDS-PAGE Then lysates using FLAG beads and STAT3-V5 was detected by western 
blotting using anti-V5 antibodies (A). The expression of STAT3-V5 (C), NFI-X3FL and 
the NFI-X3FL C-terminus deletion mutants (B) were determined in total lysates by 
western blotting.    
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The N-terminus alpha-helix is required for NFI-X3 and STAT3 interaction.  
 Co-Immunoprecipitation done with STAT3-V5 and C-terminus deletions of NFI-
X3FL showed that the N-terminus is sufficient for the interaction between STAT3 and 
NFI-X3 (Figure 5A).  Thus, the N-terminal alpha-helix was deleted (Figure 6). This 
deletion mutant, NFI-X3FL-NT del, was made by deleting the N-terminal alpha helix 
(Figure 6).  Plasmid containing this deletion was digested with HindIII and showed 
fragments of 4729 and 1161 bases (Figure 7).  HEK293 cells were then co-transfected with 
1 µg of NFI-X3FL-NT del and 1 µg of STAT3-V5 plasmids. .  Cells transfected with 
pFLAG5A was used as a negative control and cells transfected with NFI-X3FL served as a 
positive control. After cells were lysed, they were run on SDS-PAGE and expression of 
both plasmids was checked via Western Blot analysis.  Indeed, these cells do express both 
STAT3-V5 (92 kDa) (Figure 8C) and NFI-X3FL-NT del (46 kDa) (Figure 8B).  Then, Co-
IP was performed and samples ran on SDS-PAGE and analyzed by Western Blot (Figure 
8A).  The results show that NFI-X3FL-NT del does not interact with STAT3.  Hence, the 
alpha-helix is required for the interaction of NFI-X3 with STAT3.   
24 
 
Figure 6: NFI-X3FL-NT deletion. Synthetic oligonucleotides were used to create a 
deletion mutant of NFI-X3FL. This mutant was created using the NFI-X3FL as a template 
and using the QuikChange® Site-Directed Mutagenesis kit and protocol. In this mutant, 
the α-helical domain is deleted, as depicted below.  NFI-X3 consists of N-terminal α-helix, 
DNA-binding domain as well as four conserved Cysteines within DNA-binding domain. 
On the C-terminus, NFI-X3 contains a transcriptional activation (TA) domain.   
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Figure 7: NFI-X3FL-NT del plasmid digestion with HindIII. Synthetic oligonucleotides 
were used to delete the alpha-helical domain of NFI-X3FL using the full length NFI-X3FL 
as a template and following QuikChange® II Site-Directed Mutagensis Kit protocol. 
Plasmid containing this deletion was purified and digested with HindIII. Digestion map 
showing the sizes of the predicted fragments of NT del containing NFI-X3FL was created 
using the ApE program. 
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Figure 8: The α-helical domain of NFI-X3 is required for its interaction with STAT3. 
NFI-containing complexes were immunoprecipitated from HEK293 cells co-transfected 
with 1 µg of both STAT3 and empty vector, full-length NFI-X3 or NFI-X3 containing NT 
del using FLAG beads and STAT3-V5 was detected by western blotting using anti-V5 
antibodies (A). The expression of STAT3-V5 (C), NFI-X3FL and the NFI-X3FL NT 
deletion mutants (B) were determined in total lysates by western blotting.    
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NFI-X3 forms a complex with STAT3 and regulates YKL-40 expression via direct 
binding.  
Moreover, a construct containing point mutations of two conserved cysteine 
residues was made to assess whether NFI-X3 directly binds to the YKL-40 promoter to 
induce its expression in GBMs (Figure 9).  This plasmid, NFI-X3FL-C148L, C154L 
mutation was digested with PvuII into four fragments, 2515, 1858, 1297 and 445 bases 
(Figure 10).   U373 stable cells were created by co-transfecting the cells with 4 µg of NFI-
X3FL- C148L, C154L mutation plasmid and 0.2 µg of a second plasmid containing either 
zeocine or hygromycin resistance gene.  Cells were then selected in DMEM containing 100 
µg/ml hygromycin and 300 µg/ml zeocine.  Cells were then lysed and run on SDS-PAGE 
and analyzed by Western Blot for their expression of NFI-X3FL –C148L, C154L mutation 
(56 kDa) (Results not shown). Moreover, RNA was isolated from these cells using TRizol 
protocol (see materials and methods) and qPCR was performed to assess the expression of 
YKL-40 and GFAP (Figure 11). The expression of both GFAP and YKL-40 was 
significantly reduced in cells containing mutations in the DNA binding domain of NFI-X3 
compared to cells that contained full-length NFI-X3 (Figure 11).    
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Figure 9: NFI-X3FL-C148L, C154L point mutations. Synthetic oligonucleotides were 
used to create a mutant of NFI-X3FL to abolish its DNA-binding ability. This mutant was 
created using the NFI-X3FL as a template and using the QuikChange® Site-Directed 
Mutagenesis kit and protocol. On the C-terminus, NFI-X3 contains a transcriptional 
activation (TA) domain.  On the N-terminus, NFI-X3 contains an α-helix, DNA-binding 
domain as well as four conserved Cysteines within DNA-binding domain. Two of these 
conserved cysteines (C148 and C154) within the DNA binding domain were mutated to 
leucines, as depicted below.   
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Figure 10: NFI-X3FL-C148L, C154L plasmid digestion with PvuII. Synthetic 
oligonucleotides were used to mutate C148 and C154 of NFI-X3FL to leucines using the 
full length NFI-X3FL as a template and following QuikChange® II Site-Directed 
Mutagensis Kit protocol. Plasmid containing these point mutations was purified and 
digested with PvuII. Digestion map showing the sizes of the predicted fragments after 
digestion with PvuII was created using the ApE program.  
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Figure 11: The DNA-binding domain of NFI-X3 is required to induce YKL-40 
expression.  Pools of U373 stable clones transfected with plasmids expressing either full-
length NFI-X3 or NFI-X3-C148L, C154L mutant or empty vector were cultured as 
described in materials and methods.  RNA was isolated from these cells and reverse 
transcribed, and the expression of GFAP (A) and YKL-40 (B) was analyzed by qPCR.    
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All NFI-X3FL constructs can translocate to the nucleus.  
 Staining was done to assess the ability of our NFI-X3FL deletion constructs to 
translocate to the nucleus.  HEK cells were transfected with 1 µg of pFLAG5A vector, 
NFI-X3FL, NFI-X3FL-del 1, NFI-X3FL-del 2, NFI-X3FL-del 3, NFI-X3FL-NT del and 
NFI-X3FL-C148L, C154L mutation.  Twenty-four hours after transfection, cells were 
washed and fixed onto cover slips and incubated overnight with anti-FLAG antibody 
(1:100 dilutions).  The next day, cells were washed and incubated with Alexa Fluor® 488 
anti-mouse IgG antibody (1:400 dilutions) for thirty minutes in the dark.  The cells were 
then washed and incubated with Hoescht (50ng/ml) for 3 minutes, washed, and mounted 
onto slides and pictures taken.  Cells that contain FLAG epitope are green and the nuclei 
are stained blue.  Cells transfected with pFLAG5A was used as a negative control and cells 
transfected with NFI-X3FL served as a positive control.  Figure 12 shows that NFI-X3FL-
del 1 was mainly in the nucleus, while NFI-X3FL-del 2 and NFI-X3FL-del 3 were both 
cytoplamic and nuclear.  However, NFI-X3FL-del 2 was located mainly in the cytoplasm. 
NFI-X3FL-NT del was located both in the cytoplasm and nucleus, whereas NFI-X3FL-
C148L, C154L mutation was mostly located in the nucleus.     
 
32 
 
Figure 12: All of the NFI-X3FL constructs can localize to the nucleus. Plasmids 
containing either full length NFI-X3FL or NFI-X3FL deletion mutants or empty vector 
were transfected into HEK293 cells and stained with Alexa Fluoro 488 anti-mouse IgG to 
recognize the FLAG epitope and Hoescht (similar to DAPI) for nuclear staining and 
visualized by Fluorescent Microscopy.    
 
 
33 
 
Discussion 
Malignant glioblastoma (GBM) are highly invasive and resistant to radiation and 
other treatments.  As a result, patients with GBMs have poor prognosis. Recent research 
has shown that a secreted ECM protein, YKL-40, is highly expressed in GBMs and that its 
high expression is associated with the GBMs’ resistance to radiation as well as its invasive 
nature (Nigro et al., 2005 and Francescone et al., 2011).  However, how this expression of 
YKL-40 in GBMs is regulated is not known.  Recently, Singh et al. (2011) showed that 
YKL-40 is regulated by Nuclear Factor I-X3 (NFI-X3) and Signal Transducers and 
Activator of Transcription 3 (STAT3), which can form a complex. Moreover, Singh et al., 
(2011) showed that the binding of both STAT3 and NFI-X3 is required for the expression 
of the astrocyte marker, Green Fibrillary Acidic Protein (GFAP).   
 In this study, we set out to find the domains of NFI-X3 that are required for the 
formation of this complex.  First, deletions were made by removing 84, 184 and 284 amino 
acids from the C-terminus of NFI-X3.  Co-Immunoprecipitation experiments carried out 
with these deletions show that STAT3 and NFI-X3 do indeed form a complex and that, the 
N-terminus of NFI-X3 is sufficient for its interaction with STAT3 (Figure 5). However, the 
interaction is diminished in these deletions, suggesting that the C-terminus may stabilize 
this interaction.  The C-terminal transcriptional activation (TA) domain is rich in prolines, 
which play an important role in regulating protein-protein interactions.  Thus, these 
prolines might play a role in stabilizing the interaction between STAT3 and NFI-X3. To 
further elucidate which N-terminus domains are required, the alpha-helical domain of NFI-
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X3 was deleted.  Co-Immunoprecipitation with this deletion and STAT3 shows that the 
alpha-helical domain is indispensable for this interaction (Figure 8).  NFI genes can 
undergo alternative splicing, affecting mostly their C-terminus, to generate transcription 
factors with diverse functions.  Grunder et al., 2003 showed that splice variants of NFI-A, 
NFI-B and NFI-C are active transcription factors.  It would be of great interest to assess 
whether these NFI-X3 C-terminus deletion mutants are active and if they regulate genes 
that are distinct from those controlled by NFI-X3.     
We also show that all of the NFI-X3 constructs that we created are capable of 
translocating to the nucleus (Figure 12).  NFI proteins contain two nuclear localization 
signals (NLS) located on exon 2 and exons 3-6.  The NLS located on exon 2 (NLS1) is 
composed of 24 amino acids (aa 36-50), RKRKYFKKHEKRMSK while the NLS located 
on exon 3-6 (NLS2) is composed of 34 amino acids (aa 251-284), 
RRSITSPPSTSTTKRPK (Imagawag et al. 2008).  Complete nuclear localization requires 
both signals, although, one signal is sufficient for some localization.  NFI-X3FL-del 1, 
NFI-X3FL-del 2, and NFI-X3FL C148L, C154L mutation constructs contain both nuclear 
localization signals.  However, NFI-X3FL-del 3 contains only NLS1, whereas NFI-X3FL-
NT del contains only NLS2.  As a result, these constructs do not localize to the nucleus as 
well as those that contains both NLS signals.  Most importantly, the ability of these 
constructs to localize to the nucleus does not affect their capacity to interact with STAT3 
as it shuttles between the cytoplasm and nucleus (Meyer and Vinkemeier, 2004) resulting 
in a steady state subcellular distribution that results from continuous nuclear import and 
export (Pranada et al., 2004).   
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We also wanted to assess whether NFI-X3 and STAT3 regulate YKL-40 expression 
by binding directly to the gene, like that shown for GFAP expression.    In order to test 
this, NFI-X3FL containing point mutations within the DNA binding domain was created 
(Figure 9).  Novak et al., (1992) showed that three (C104, 120 and 163) of the four 
conserved cysteine residues within the DNA binding domain of NFI-C are required for 
DNA binding. In our construct, Cys 148 and 154, corresponding to Cys 104 and 120, were 
mutated to leucines.  Stably transfected U373 cells containing this construct show that the 
DNA binding domain of NFI-X3 is required to induce YKL-40 expression (Figure 11). 
This suggests that NFI-X3 binds directly to the YKL-40 promoter.  Indeed, Singh et al., 
(2011) showed that NFI-X3 binds to NFI elements in glioma cells and it may be recruited 
together with STAT3. Investigation of the molecular mechanism of NFI-mediated gene 
activation has led to discoveries that NFIs bind to their specific binding elements, but can 
also interact with histone H3 (Muller and Mermod, 2000) and remodeling complexes, 
including Brg1 (Zhao et al., 2005).  It will be important to determine if chromatin 
remodeling is a mechanism regulating NFI-dependent transcription of YKL-40.  Singh et 
al., (2011) also showed that both NFI-X3 and STAT3 weakly bind to the adjacently 
located NFI and STAT elements on the YKL-40 promoter.  Therefore, STAT3 may 
stabilize the weak binding of NFI-X3 and also recruit NFI-X3 to the YKL-40 promoter.  
Further investigation is required to determine the involvement of other transcription factors 
that may form complexes with STAT3 and NFI-X3.  It is also important to determine if 
these transcription factors can form an enhanceosome with cooperative binding, like that of 
the IFN-β enhanceosome (Escalante et al., 2007).   More exploration is also needed to 
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determine the subset of genes that are regulated by the STAT3 and NFI-X3 complex.  In 
summary, we propose that NFI-X3 and STAT3 form a complex via the alpha-helical 
domain of NFI-X3 and this complex induces YKL-40 expression by stabilizing the weak 
binding of NFI-X3 to the YKL-40 promoter.    
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